APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

AI Oncology/Cancer Early Screening

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global AI Oncology/Cancer Early Screening Market Outlook and Growth Opportunities 2026

15 April 2026Not stated

Choose your research edition.

Industry ResearchAI Oncology/Cancer Early Screening Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal AI Oncology/Cancer Early Screening Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal AI Oncology/Cancer Early Screening Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal AI Oncology/Cancer Early Screening Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal AI Oncology/Cancer Early Screening Market Analysis and Forecast 2026-2032180 pages · $4,950 USD

Market perspective

The global AI Oncology/Cancer Early Screening market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for AI Oncology/Cancer Early Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for AI Oncology/Cancer Early Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for AI Oncology/Cancer Early Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the AI Oncology/Cancer Early Screening market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the AI Oncology/Cancer Early Screening market include Tempus AI, Grail, Guardant Health, PathAI, Google(DeepMind), Philips Healthcare, IBM, Azra AI and Siemens Healthineers, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global AI Oncology/Cancer Early Screening market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of AI Oncology/Cancer Early Screening and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents AI Oncology/Cancer Early Screening revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global AI Oncology/Cancer Early Screening market.

AI Oncology/Cancer Early Screening Segment by Company

Tempus AI

Grail

Guardant Health

PathAI

Google(DeepMind)

Philips Healthcare

IBM

Azra AI

Siemens Healthineers

GE Healthcare

Intel

ConcertAI

NVIDIA Developer

Digital Diagnostics

Median Technologies

Alibaba Group

ByteDance

BGI Genomics

Guangzhou Kingmed Diagnostics Group Co., Ltd.

Amoy Diagnostics Co.,Ltd.

Tencent Miying

AI Oncology/Cancer Early Screening Segment by Type

Based on Medical Imaging

Based on Multi-omics Data

AI Oncology/Cancer Early Screening Segment by Application

Lung Cancer

Digestive System Tumors (Colorectal Cancer/Pancreatic Cancer/Liver Cancer/Gastric Cancer)

Breast Cancer and Gynecological Tumors (Ovarian Cancer/Cervical Cancer)

Urinary System Tumors (Bladder Cancer)

Central Nervous System Tumors

Soft Tissue and Bone Tumors

Thyroid Cancer and Melanoma

AI Oncology/Cancer Early Screening Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global AI Oncology/Cancer Early Screening status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the AI Oncology/Cancer Early Screening key companies, revenue, market share, and recent developments.

3. To split the AI Oncology/Cancer Early Screening breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions AI Oncology/Cancer Early Screening market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify AI Oncology/Cancer Early Screening significant trends, drivers, influence factors in global and regions.

6. To analyze AI Oncology/Cancer Early Screening competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AI Oncology/Cancer Early Screening market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of AI Oncology/Cancer Early Screening and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AI Oncology/Cancer Early Screening.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global AI Oncology/Cancer Early Screening industry.

Chapter 3: Detailed analysis of AI Oncology/Cancer Early Screening company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of AI Oncology/Cancer Early Screening in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of AI Oncology/Cancer Early Screening in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. AI Oncology/Cancer Early Screening Industry Trends Table 2. AI Oncology/Cancer Early Screening Industry Drivers Table 3. AI Oncology/Cancer Early Screening Industry Opportunities and Challenges Table 4. AI Oncology/Cancer Early Screening Industry Restraints Table 5. Global AI Oncology/Cancer Early Screening Revenue by Company (US$ Million) & (2021-2026) Table 6. Global AI Oncology/Cancer Early Screening Revenue Share by Company (2021-2026) Table 7. Global AI Oncology/Cancer Early Screening Company Ranking, (2024-2026) & (US$ Million) Table 8. Global AI Oncology/Cancer Early Screening Key Company Manufacturing Base & Headquarters Table 9. Global AI Oncology/Cancer Early Screening Company, Product Type & Application Table 10. Global AI Oncology/Cancer Early Screening Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global AI Oncology/Cancer Early Screening by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Based on Medical Imaging Table 15. Significant Companies of Based on Multi-omics Data Table 16. Global AI Oncology/Cancer Early Screening Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global AI Oncology/Cancer Early Screening Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global AI Oncology/Cancer Early Screening Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global AI Oncology/Cancer Early Screening Sales Value Share by Type (2021-2026) Table 20. Global AI Oncology/Cancer Early Screening Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Lung Cancer Table 22. Significant Companies of Digestive System Tumors (Colorectal Cancer/Pancreatic Cancer/Liver Cancer/Gastric Cancer) Table 23. Significant Companies of Breast Cancer and Gynecological Tumors (Ovarian Cancer/Cervical Cancer) Table 24. Significant Companies of Urinary System Tumors (Bladder Cancer) Table 25. Significant Companies of Central Nervous System Tumors Table 26. Significant Companies of Soft Tissue and Bone Tumors Table 27. Significant Companies of Thyroid Cancer and Melanoma Table 28. Global AI Oncology/Cancer Early Screening Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global AI Oncology/Cancer Early Screening Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global AI Oncology/Cancer Early Screening Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global AI Oncology/Cancer Early Screening Sales Value Share by Application (2021-2026) Table 32. Global AI Oncology/Cancer Early Screening Sales Value Share by Application (2027-2032) Table 33. Global AI Oncology/Cancer Early Screening Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global AI Oncology/Cancer Early Screening Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global AI Oncology/Cancer Early Screening Sales Value Share by Region (2021-2026) Table 36. Global AI Oncology/Cancer Early Screening Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global AI Oncology/Cancer Early Screening Sales Value Share by Region (2027-2032) Table 38. Global AI Oncology/Cancer Early Screening Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global AI Oncology/Cancer Early Screening Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global AI Oncology/Cancer Early Screening Sales Value Market Share by Country (2021-2026) Table 41. Global AI Oncology/Cancer Early Screening Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global AI Oncology/Cancer Early Screening Sales Value Market Share by Country (2027-2032) Table 43. Tempus AI Company Information Table 44. Tempus AI Business Overview Table 45. Tempus AI AI Oncology/Cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Tempus AI AI Oncology/Cancer Early Screening Product Portfolio Table 47. Tempus AI Recent Development Table 48. Grail Company Information Table 49. Grail Business Overview Table 50. Grail AI Oncology/Cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Grail AI Oncology/Cancer Early Screening Product Portfolio Table 52. Grail Recent Development Table 53. Guardant Health Company Information Table 54. Guardant Health Business Overview Table 55. Guardant Health AI Oncology/Cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Guardant Health AI Oncology/Cancer Early Screening Product Portfolio Table 57. Guardant Health Recent Development Table 58. PathAI Company Information Table 59. PathAI Business Overview Table 60. PathAI AI Oncology/Cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. PathAI AI Oncology/Cancer Early Screening Product Portfolio Table 62. PathAI Recent Development Table 63. Google(DeepMind) Company Information Table 64. Google(DeepMind) Business Overview Table 65. Google(DeepMind) AI Oncology/Cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Google(DeepMind) AI Oncology/Cancer Early Screening Product Portfolio Table 67. Google(DeepMind) Recent Development Table 68. Philips Healthcare Company Information Table 69. Philips Healthcare Business Overview Table 70. Philips Healthcare AI Oncology/Cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Philips Healthcare AI Oncology/Cancer Early Screening Product Portfolio Table 72. Philips Healthcare Recent Development Table 73. IBM Company Information Table 74. IBM Business Overview Table 75. IBM AI Oncology/Cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. IBM AI Oncology/Cancer Early Screening Product Portfolio Table 77. IBM Recent Development Table 78. Azra AI Company Information Table 79. Azra AI Business Overview Table 80. Azra AI AI Oncology/Cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Azra AI AI Oncology/Cancer Early Screening Product Portfolio Table 82. Azra AI Recent Development Table 83. Siemens Healthineers Company Information Table 84. Siemens Healthineers Business Overview Table 85. Siemens Healthineers AI Oncology/Cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Siemens Healthineers AI Oncology/Cancer Early Screening Product Portfolio Table 87. Siemens Healthineers Recent Development Table 88. GE Healthcare Company Information Table 89. GE Healthcare Business Overview Table 90. GE Healthcare AI Oncology/Cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. GE Healthcare AI Oncology/Cancer Early Screening Product Portfolio Table 92. GE Healthcare Recent Development Table 93. Intel Company Information Table 94. Intel Business Overview Table 95. Intel AI Oncology/Cancer Early Screening Sales (Unit), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Intel AI Oncology/Cancer Early Screening Product Portfolio Table 97. Intel Recent Development Table 98. ConcertAI Company Information Table 99. ConcertAI Business Overview Table 100. ConcertAI AI Oncology/Cancer Early Screening Sales (Unit), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. ConcertAI AI Oncology/Cancer Early Screening Product Portfolio Table 102. ConcertAI Recent Development Table 103. NVIDIA Developer Company Information Table 104. NVIDIA Developer Business Overview Table 105. NVIDIA Developer AI Oncology/Cancer Early Screening Sales (Unit), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. NVIDIA Developer AI Oncology/Cancer Early Screening Product Portfolio Table 107. NVIDIA Developer Recent Development Table 108. Digital Diagnostics Company Information Table 109. Digital Diagnostics Business Overview Table 110. Digital Diagnostics AI Oncology/Cancer Early Screening Sales (Unit), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Digital Diagnostics AI Oncology/Cancer Early Screening Product Portfolio Table 112. Digital Diagnostics Recent Development Table 113. Median Technologies Company Information Table 114. Median Technologies Business Overview Table 115. Median Technologies AI Oncology/Cancer Early Screening Sales (Unit), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Median Technologies AI Oncology/Cancer Early Screening Product Portfolio Table 117. Median Technologies Recent Development Table 118. Alibaba Group Company Information Table 119. Alibaba Group Business Overview Table 120. Alibaba Group AI Oncology/Cancer Early Screening Sales (Unit), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 121. Alibaba Group AI Oncology/Cancer Early Screening Product Portfolio Table 122. Alibaba Group Recent Development Table 123. ByteDance Company Information Table 124. ByteDance Business Overview Table 125. ByteDance AI Oncology/Cancer Early Screening Sales (Unit), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 126. ByteDance AI Oncology/Cancer Early Screening Product Portfolio Table 127. ByteDance Recent Development Table 128. BGI Genomics Company Information Table 129. BGI Genomics Business Overview Table 130. BGI Genomics AI Oncology/Cancer Early Screening Sales (Unit), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 131. BGI Genomics AI Oncology/Cancer Early Screening Product Portfolio Table 132. BGI Genomics Recent Development Table 133. Guangzhou Kingmed Diagnostics Group Co., Ltd. Company Information Table 134. Guangzhou Kingmed Diagnostics Group Co., Ltd. Business Overview Table 135. Guangzhou Kingmed Diagnostics Group Co., Ltd. AI Oncology/Cancer Early Screening Sales (Unit), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 136. Guangzhou Kingmed Diagnostics Group Co., Ltd. AI Oncology/Cancer Early Screening Product Portfolio Table 137. Guangzhou Kingmed Diagnostics Group Co., Ltd. Recent Development Table 138. Amoy Diagnostics Co.,Ltd. Company Information Table 139. Amoy Diagnostics Co.,Ltd. Business Overview Table 140. Amoy Diagnostics Co.,Ltd. AI Oncology/Cancer Early Screening Sales (Unit), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 141. Amoy Diagnostics Co.,Ltd. AI Oncology/Cancer Early Screening Product Portfolio Table 142. Amoy Diagnostics Co.,Ltd. Recent Development Table 143. Tencent Miying Company Information Table 144. Tencent Miying Business Overview Table 145. Tencent Miying AI Oncology/Cancer Early Screening Sales (Unit), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 146. Tencent Miying AI Oncology/Cancer Early Screening Product Portfolio Table 147. Tencent Miying Recent Development Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources Table 151. Primary Sources List of Figures Figure 1. AI Oncology/Cancer Early Screening Product Image Figure 2. Global AI Oncology/Cancer Early Screening Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global AI Oncology/Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 4. Global AI Oncology/Cancer Early Screening Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Based on Medical Imaging Image Figure 8. Based on Multi-omics Data Image Figure 9. Global AI Oncology/Cancer Early Screening Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global AI Oncology/Cancer Early Screening Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global AI Oncology/Cancer Early Screening Sales Value Share by Type (2021-2032) Figure 12. Lung Cancer Image Figure 13. Digestive System Tumors (Colorectal Cancer/Pancreatic Cancer/Liver Cancer/Gastric Cancer) Image Figure 14. Breast Cancer and Gynecological Tumors (Ovarian Cancer/Cervical Cancer) Image Figure 15. Urinary System Tumors (Bladder Cancer) Image Figure 16. Central Nervous System Tumors Image Figure 17. Soft Tissue and Bone Tumors Image Figure 18. Thyroid Cancer and Melanoma Image Figure 19. Global AI Oncology/Cancer Early Screening Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global AI Oncology/Cancer Early Screening Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global AI Oncology/Cancer Early Screening Sales Value Share by Application (2021-2032) Figure 22. Global AI Oncology/Cancer Early Screening Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global AI Oncology/Cancer Early Screening Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America AI Oncology/Cancer Early Screening Sales Value (2021-2032) & (US$ Million) Figure 25. North America AI Oncology/Cancer Early Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe AI Oncology/Cancer Early Screening Sales Value (2021-2032) & (US$ Million) Figure 27. Europe AI Oncology/Cancer Early Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific AI Oncology/Cancer Early Screening Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific AI Oncology/Cancer Early Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America AI Oncology/Cancer Early Screening Sales Value (2021-2032) & (US$ Million) Figure 31. South America AI Oncology/Cancer Early Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa AI Oncology/Cancer Early Screening Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa AI Oncology/Cancer Early Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Based on Medical Imaging
  • Based on Multi-omics Data
Applications
  • Lung Cancer
  • Digestive System Tumors (Colorectal Cancer/Pancreatic Cancer/Liver Cancer/Gastric Cancer)
  • Breast Cancer and Gynecological Tumors (Ovarian Cancer/Cervical Cancer)
  • Urinary System Tumors (Bladder Cancer)
  • Central Nervous System Tumors
  • Soft Tissue and Bone Tumors
  • Thyroid Cancer and Melanoma
Companies covered
  • Tempus AI
  • Grail
  • Guardant Health
  • PathAI
  • Google(DeepMind)
  • Philips Healthcare
  • IBM
  • Azra AI
  • Siemens Healthineers
  • GE Healthcare
  • Intel
  • ConcertAI
  • NVIDIA Developer
  • Digital Diagnostics
  • Median Technologies
  • Alibaba Group
  • ByteDance
  • BGI Genomics
  • Guangzhou Kingmed Diagnostics Group Co., Ltd.
  • Amoy Diagnostics Co.,Ltd.
  • Tencent Miying

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global AI Oncology/Cancer Early Screening Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global AI Oncology/Cancer Early Screening Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 AI Oncology/Cancer Early Screening Market Dynamics
  1. 2.1 AI Oncology/Cancer Early Screening Industry Trends
  2. 2.2 AI Oncology/Cancer Early Screening Industry Drivers
  3. 2.3 AI Oncology/Cancer Early Screening Industry Opportunities and Challenges
  4. 2.4 AI Oncology/Cancer Early Screening Industry Restraints
3 AI Oncology/Cancer Early Screening Market by Company
  1. 3.1 Global AI Oncology/Cancer Early Screening Company Revenue Ranking in 2025
  2. 3.2 Global AI Oncology/Cancer Early Screening Revenue by Company (2021-2026)
  3. 3.3 Global AI Oncology/Cancer Early Screening Company Ranking (2024-2026)
  4. 3.4 Global AI Oncology/Cancer Early Screening Company Manufacturing Base and Headquarters
  5. 3.5 Global AI Oncology/Cancer Early Screening Company Product Type and Application
  6. 3.6 Global AI Oncology/Cancer Early Screening Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global AI Oncology/Cancer Early Screening Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 AI Oncology/Cancer Early Screening Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 AI Oncology/Cancer Early Screening Market by Type
  1. 4.1 AI Oncology/Cancer Early Screening Type Introduction
  2. 4.1.1 Based on Medical Imaging
  3. 4.1.2 Based on Multi-omics Data
  4. 4.2 Global AI Oncology/Cancer Early Screening Sales Value by Type
  5. 4.2.1 Global AI Oncology/Cancer Early Screening Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global AI Oncology/Cancer Early Screening Sales Value by Type (2021-2032)
  7. 4.2.3 Global AI Oncology/Cancer Early Screening Sales Value Share by Type (2021-2032)
5 AI Oncology/Cancer Early Screening Market by Application
  1. 5.1 AI Oncology/Cancer Early Screening Application Introduction
  2. 5.1.1 Lung Cancer
  3. 5.1.2 Digestive System Tumors (Colorectal Cancer/Pancreatic Cancer/Liver Cancer/Gastric Cancer)
  4. 5.1.3 Breast Cancer and Gynecological Tumors (Ovarian Cancer/Cervical Cancer)
  5. 5.1.4 Urinary System Tumors (Bladder Cancer)
  6. 5.1.5 Central Nervous System Tumors
  7. 5.1.6 Soft Tissue and Bone Tumors
  8. 5.1.7 Thyroid Cancer and Melanoma
  9. 5.2 Global AI Oncology/Cancer Early Screening Sales Value by Application
  10. 5.2.1 Global AI Oncology/Cancer Early Screening Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.2.2 Global AI Oncology/Cancer Early Screening Sales Value by Application (2021-2032)
  12. 5.2.3 Global AI Oncology/Cancer Early Screening Sales Value Share by Application (2021-2032)
6 AI Oncology/Cancer Early Screening Regional Value Analysis
  1. 6.1 Global AI Oncology/Cancer Early Screening Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global AI Oncology/Cancer Early Screening Sales Value by Region (2021-2032)
  3. 6.2.1 Global AI Oncology/Cancer Early Screening Sales Value by Region: 2021-2026
  4. 6.2.2 Global AI Oncology/Cancer Early Screening Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America AI Oncology/Cancer Early Screening Sales Value (2021-2032)
  7. 6.3.2 North America AI Oncology/Cancer Early Screening Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe AI Oncology/Cancer Early Screening Sales Value (2021-2032)
  10. 6.4.2 Europe AI Oncology/Cancer Early Screening Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific AI Oncology/Cancer Early Screening Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific AI Oncology/Cancer Early Screening Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America AI Oncology/Cancer Early Screening Sales Value (2021-2032)
  16. 6.6.2 South America AI Oncology/Cancer Early Screening Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa AI Oncology/Cancer Early Screening Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa AI Oncology/Cancer Early Screening Sales Value Share by Country, 2025 VS 2032
7 AI Oncology/Cancer Early Screening Country-level Value Analysis
  1. 7.1 Global AI Oncology/Cancer Early Screening Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global AI Oncology/Cancer Early Screening Sales Value by Country (2021-2032)
  3. 7.2.1 Global AI Oncology/Cancer Early Screening Sales Value by Country (2021-2026)
  4. 7.2.2 Global AI Oncology/Cancer Early Screening Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt AI Oncology/Cancer Early Screening Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt AI Oncology/Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt AI Oncology/Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Tempus AI
  2. 8.1.1 Tempus AI Company Information
  3. 8.1.2 Tempus AI Business Overview
  4. 8.1.3 Tempus AI AI Oncology/Cancer Early Screening Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Tempus AI AI Oncology/Cancer Early Screening Product Portfolio
  6. 8.1.5 Tempus AI Recent Developments
  7. 8.2 Grail
  8. 8.2.1 Grail Company Information
  9. 8.2.2 Grail Business Overview
  10. 8.2.3 Grail AI Oncology/Cancer Early Screening Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Grail AI Oncology/Cancer Early Screening Product Portfolio
  12. 8.2.5 Grail Recent Developments
  13. 8.3 Guardant Health
  14. 8.3.1 Guardant Health Company Information
  15. 8.3.2 Guardant Health Business Overview
  16. 8.3.3 Guardant Health AI Oncology/Cancer Early Screening Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Guardant Health AI Oncology/Cancer Early Screening Product Portfolio
  18. 8.3.5 Guardant Health Recent Developments
  19. 8.4 PathAI
  20. 8.4.1 PathAI Company Information
  21. 8.4.2 PathAI Business Overview
  22. 8.4.3 PathAI AI Oncology/Cancer Early Screening Revenue and Gross Margin (2021-2026)
  23. 8.4.4 PathAI AI Oncology/Cancer Early Screening Product Portfolio
  24. 8.4.5 PathAI Recent Developments
  25. 8.5 Google(DeepMind)
  26. 8.5.1 Google(DeepMind) Company Information
  27. 8.5.2 Google(DeepMind) Business Overview
  28. 8.5.3 Google(DeepMind) AI Oncology/Cancer Early Screening Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Google(DeepMind) AI Oncology/Cancer Early Screening Product Portfolio
  30. 8.5.5 Google(DeepMind) Recent Developments
  31. 8.6 Philips Healthcare
  32. 8.6.1 Philips Healthcare Company Information
  33. 8.6.2 Philips Healthcare Business Overview
  34. 8.6.3 Philips Healthcare AI Oncology/Cancer Early Screening Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Philips Healthcare AI Oncology/Cancer Early Screening Product Portfolio
  36. 8.6.5 Philips Healthcare Recent Developments
  37. 8.7 IBM
  38. 8.7.1 IBM Company Information
  39. 8.7.2 IBM Business Overview
  40. 8.7.3 IBM AI Oncology/Cancer Early Screening Revenue and Gross Margin (2021-2026)
  41. 8.7.4 IBM AI Oncology/Cancer Early Screening Product Portfolio
  42. 8.7.5 IBM Recent Developments
  43. 8.8 Azra AI
  44. 8.8.1 Azra AI Company Information
  45. 8.8.2 Azra AI Business Overview
  46. 8.8.3 Azra AI AI Oncology/Cancer Early Screening Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Azra AI AI Oncology/Cancer Early Screening Product Portfolio
  48. 8.8.5 Azra AI Recent Developments
  49. 8.9 Siemens Healthineers
  50. 8.9.1 Siemens Healthineers Company Information
  51. 8.9.2 Siemens Healthineers Business Overview
  52. 8.9.3 Siemens Healthineers AI Oncology/Cancer Early Screening Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Siemens Healthineers AI Oncology/Cancer Early Screening Product Portfolio
  54. 8.9.5 Siemens Healthineers Recent Developments
  55. 8.10 GE Healthcare
  56. 8.10.1 GE Healthcare Company Information
  57. 8.10.2 GE Healthcare Business Overview
  58. 8.10.3 GE Healthcare AI Oncology/Cancer Early Screening Revenue and Gross Margin (2021-2026)
  59. 8.10.4 GE Healthcare AI Oncology/Cancer Early Screening Product Portfolio
  60. 8.10.5 GE Healthcare Recent Developments
  61. 8.11 Intel
  62. 8.11.1 Intel Company Information
  63. 8.11.2 Intel Business Overview
  64. 8.11.3 Intel AI Oncology/Cancer Early Screening Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Intel AI Oncology/Cancer Early Screening Product Portfolio
  66. 8.11.5 Intel Recent Developments
  67. 8.12 ConcertAI
  68. 8.12.1 ConcertAI Company Information
  69. 8.12.2 ConcertAI Business Overview
  70. 8.12.3 ConcertAI AI Oncology/Cancer Early Screening Revenue and Gross Margin (2021-2026)
  71. 8.12.4 ConcertAI AI Oncology/Cancer Early Screening Product Portfolio
  72. 8.12.5 ConcertAI Recent Developments
  73. 8.13 NVIDIA Developer
  74. 8.13.1 NVIDIA Developer Company Information
  75. 8.13.2 NVIDIA Developer Business Overview
  76. 8.13.3 NVIDIA Developer AI Oncology/Cancer Early Screening Revenue and Gross Margin (2021-2026)
  77. 8.13.4 NVIDIA Developer AI Oncology/Cancer Early Screening Product Portfolio
  78. 8.13.5 NVIDIA Developer Recent Developments
  79. 8.14 Digital Diagnostics
  80. 8.14.1 Digital Diagnostics Company Information
  81. 8.14.2 Digital Diagnostics Business Overview
  82. 8.14.3 Digital Diagnostics AI Oncology/Cancer Early Screening Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Digital Diagnostics AI Oncology/Cancer Early Screening Product Portfolio
  84. 8.14.5 Digital Diagnostics Recent Developments
  85. 8.15 Median Technologies
  86. 8.15.1 Median Technologies Company Information
  87. 8.15.2 Median Technologies Business Overview
  88. 8.15.3 Median Technologies AI Oncology/Cancer Early Screening Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Median Technologies AI Oncology/Cancer Early Screening Product Portfolio
  90. 8.15.5 Median Technologies Recent Developments
  91. 8.16 Alibaba Group
  92. 8.16.1 Alibaba Group Company Information
  93. 8.16.2 Alibaba Group Business Overview
  94. 8.16.3 Alibaba Group AI Oncology/Cancer Early Screening Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Alibaba Group AI Oncology/Cancer Early Screening Product Portfolio
  96. 8.16.5 Alibaba Group Recent Developments
  97. 8.17 ByteDance
  98. 8.17.1 ByteDance Company Information
  99. 8.17.2 ByteDance Business Overview
  100. 8.17.3 ByteDance AI Oncology/Cancer Early Screening Revenue and Gross Margin (2021-2026)
  101. 8.17.4 ByteDance AI Oncology/Cancer Early Screening Product Portfolio
  102. 8.17.5 ByteDance Recent Developments
  103. 8.18 BGI Genomics
  104. 8.18.1 BGI Genomics Company Information
  105. 8.18.2 BGI Genomics Business Overview
  106. 8.18.3 BGI Genomics AI Oncology/Cancer Early Screening Revenue and Gross Margin (2021-2026)
  107. 8.18.4 BGI Genomics AI Oncology/Cancer Early Screening Product Portfolio
  108. 8.18.5 BGI Genomics Recent Developments
  109. 8.19 Guangzhou Kingmed Diagnostics Group Co., Ltd.
  110. 8.19.1 Guangzhou Kingmed Diagnostics Group Co., Ltd. Company Information
  111. 8.19.2 Guangzhou Kingmed Diagnostics Group Co., Ltd. Business Overview
  112. 8.19.3 Guangzhou Kingmed Diagnostics Group Co., Ltd. AI Oncology/Cancer Early Screening Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Guangzhou Kingmed Diagnostics Group Co., Ltd. AI Oncology/Cancer Early Screening Product Portfolio
  114. 8.19.5 Guangzhou Kingmed Diagnostics Group Co., Ltd. Recent Developments
  115. 8.20 Amoy Diagnostics Co.,Ltd.
  116. 8.20.1 Amoy Diagnostics Co.,Ltd. Company Information
  117. 8.20.2 Amoy Diagnostics Co.,Ltd. Business Overview
  118. 8.20.3 Amoy Diagnostics Co.,Ltd. AI Oncology/Cancer Early Screening Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Amoy Diagnostics Co.,Ltd. AI Oncology/Cancer Early Screening Product Portfolio
  120. 8.20.5 Amoy Diagnostics Co.,Ltd. Recent Developments
  121. 8.21 Tencent Miying
  122. 8.21.1 Tencent Miying Company Information
  123. 8.21.2 Tencent Miying Business Overview
  124. 8.21.3 Tencent Miying AI Oncology/Cancer Early Screening Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Tencent Miying AI Oncology/Cancer Early Screening Product Portfolio
  126. 8.21.5 Tencent Miying Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst